Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2021

Conditions

Solid TumorNon-Hodgkin Lymphoma

Interventions

DRUG

ADG106

IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.

Trial Locations (2)

Shanghai Dongfang Hospital, Shanghai

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Adagene (Suzhou) Limited

INDUSTRY

NCT03802955 - Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter